New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Go back to New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 5.65 -0.01 (0.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.66 | 52 Week High | $45.34 | |||
| Open | $5.60 | 52 Week Low | $15.92 | |||
| Day High | $5.82 | P/E | 2.42 | |||
| Day Low | $5.60 | EPS | $2.33 | |||
| Volume | 388,714 | |||||
